drugset / Trial / NCT00006224

Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix

NCT00006224 ↗

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have persistent or recurrent cancer of the cervix.

Timeline

Start
2000-09
Primary completion
2005-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 800 mg/m2 Intravenous

Indications